EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma

Eusebio Luna Velasquez, Renil S Titus, David-Dan Nguyen, Carlos Riveros, Aly-Khan Lalani, Dharam Kaushik, Guru P Sonpavde, Petros Grivas, Christopher J D Wallis, Raj Satkunasivam

JAMA Network Open · 01.07.2026 · 9 (7) · e2621032

DOI: 10.1001/jamanetworkopen.2026.21032 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift JAMA Network Open, online erschienen am 01.07.2026. Verfasst von Eusebio Luna Velasquez und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Houston Methodist Hospital, Houston, Texas. Hauptthemen laut MEDLINE: Gemcitabine, Cisplatin, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Enfortumab vedotin plus pembrolizumab (EV/P) recently emerged as the preferred first-line treatment regimen for metastatic urothelial carcinoma (mUC), but evidence outside trial settings is relatively limited.

Objective

To evaluate outcomes associated with first-line EV/P compared with gemcitabine plus cisplatin (G/C) in patients with mUC. Design, Setting, and Participants This retrospective cohort study used the TriNetX database. Adults with mUC initiating first-line EV/P or G/C between September 2007 and September 2025 were included. Cohorts were propensity score matched for comparison by demographic characteristics, comorbidities, kidney function, and location of metastatic disease. Main Outcomes and Measures The primary outcome was overall survival (OS). Secondary outcomes included time to next treatment (TTNT), time to hospitalization within 90 days of treatment initiation (EHA), and adverse events (AEs). Outcomes were compared using Kaplan-Meier analysis and log rank test, reporting hazard ratios (HRs) and 95% CIs.

Results

The study included 4433 patients (1841 receiving EV/P and 2592 receiving G/C), with the EV/P group being significantly older (mean [SD] age, 70.6 [10.1] years vs 67.2 [10.6] years; P < .001) and having a higher proportion of Black patients (129 [6.7%] vs 139 [5.3%]; P = .04) and White patients (1445 [76.0%] vs 1614 [61.8%]) but a smaller proportion of Asian patients (145 [7.6%] vs 326 [12.5%]; P < .001). The EV/P group also carried a greater comorbidity burden, including higher rates of heart failure, diabetes, and obesity, while baseline characteristics were well balanced after propensity score matching. First line EV/P was associated with lower risk of death (HR, 0.70; 95% CI, 0.63-0.79), longer median OS (20 vs 11 months), lower risk of EHA (HR, 0.73; 95% CI, 0.64-0.83), and longer TTNT (median, 35 vs 10 months; HR, 0.49; 95% CI, 0.39-0.61). Receipt of EV/P at first line was associated with higher rates of rash, hyperglycemia, and hypothyroidism but fewer cytopenias and gastrointestinal toxic effects. Conclusions and Relevance In this retrospective cohort study of patients with mUC, EV/P was associated with longer OS, delayed TTNT, and lower time to EHA compared with G/C. These findings support the broader adoption of EV/P as first-line therapy in routine clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GemcitabineCisplatinAntineoplastic Combined Chemotherapy ProtocolsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedUrologic NeoplasmsCarcinoma, Transitional CellRetrospective StudiesKaplan-Meier EstimateHumansMaleFemaleMiddle AgedAgedAged, 80 and overProgression-Free SurvivalTime Factors

Substanzen

enfortumab vedotinpembrolizumabGemcitabineCisplatinAntibodies, MonoclonalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Urology, Houston Methodist Hospital, Houston, Texas.
  • Division of Urology and Surgical Oncology, Department of Surgery, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Ontario, Canada.
  • Department of Oncology, McMaster University, Hamilton, Ontario, Canada.
  • Division of Medical Oncology, Advent Health Cancer Institute and University of Central Florida, Orlando.
  • University of Washington School of Medicine; Fred Hutchinson Cancer Center, Seattle.
  • Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, Ontario, Canada.

Zitieren

APA

Velasquez, E. L., Titus, R. S., Nguyen, D. D., Riveros, C., Lalani, A. K., Kaushik, D., Sonpavde, G. P., Grivas, P., Wallis, C. J. D., & Satkunasivam, R. (2026). First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA Network Open, 9(7), e2621032. https://doi.org/10.1001/jamanetworkopen.2026.21032

Vancouver

Velasquez EL, Titus RS, Nguyen DD, Riveros C, Lalani AK, Kaushik D, et al. First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma. JAMA Network Open. 2026;9(7):e2621032. doi:10.1001/jamanetworkopen.2026.21032

BibTeX
@article{Velasquez2026,
  author = {Velasquez, Eusebio Luna and Titus, Renil S and Nguyen, David-Dan and Riveros, Carlos and Lalani, Aly-Khan and Kaushik, Dharam and Sonpavde, Guru P and Grivas, Petros and Wallis, Christopher J D and Satkunasivam, Raj},
  title = {First-Line Enfortumab Vedotin Plus Pembrolizumab vs Gemcitabine Plus Cisplatin for Metastatic Urothelial Carcinoma},
  journal = {JAMA Network Open},
  year = {2026},
  volume = {9},
  number = {7},
  pages = {e2621032},
  doi = {10.1001/jamanetworkopen.2026.21032}
}
Kostenlos starten →